交链孢酚单甲醚在大鼠小鼠体内的分布

对食管癌高发区粮食中分离的互隔交链孢霉的毒素交链孢酚单甲醚(AME)在大鼠、小鼠体内的分布进行研究。给动物腹腔内注射氚标记的交链孢酚单甲醚(~3H-AME),然后在不同时间测各脏器的放射性。结果表明:在所测9个脏器中,2h肝脏含量最高,食管下段在大小鼠分别居第四和第三。但大小鼠分别在72、24h则以食管下段最高,说明AME及其代谢物在此清除较慢,即对其有较高的亲和力。     

Formoterol and salbutamol inhibit bradykinin- and histamine-induced airway microvascular leakage in guinea-pig.

1. The effects of the beta 2-adrenoceptor agonists, salbutamol and formoterol, on the increase of microvascular permeability induced by histamine or bradykinin in guinea-pig airways have been studied in vivo. Extravasation of intravenously injected Evans blue dye was used as an index of permeability. The effects of salbutamol and formoterol on the increase in pulmonary airway resistance induced by histamine or bradykinin have also been studied. 2. The increase in pulmonary airway resistance induced by histamine or bradykinin was totally inhibited by salbutamol and formoterol. The ED50 of the two mediators were 0.59 +/- 0.21 (n = 5) and 0.20 +/- 0.14 (n = 5) micrograms kg-1 respectively for salbutamol, and 0.13 +/- 0.12 (n = 6) and 0.02 +/- 0.01 (n = 6) micrograms kg-1 respectively for formoterol. 3. Salbutamol (10 and 30 micrograms kg-1) and formoterol (1 and 10 micrograms kg-1) inhibited the increase of microvascular permeability induced by histamine (30 micrograms kg-1) in the guinea-pig airways. The inhibitory effect was predominant in the trachea and the main bronchi, with a maximum inhibition of 20 to 50%. The two drugs had little or no inhibitory effect on the other structures studied, viz. nasal mucosa, larynx, proximal and distal intrapulmonary airways. 4. Salbutamol and formoterol (1 and 10 micrograms kg-1) abolished the increase in microvascular permeability induced by bradykinin (0.3 micrograms kg-1). This inhibitory effect of two beta-adrenoceptor stimulants was predominant in the trachea and the nasal mucosa where it was observed with 1 microgram kg-1 of the beta-adrenoceptor agonists.(ABSTRACT TRUNCATED AT 250 WORDS)     

The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy.

BACKGROUND AND PURPOSE: The potential risk of prolongation of treatment time in cervical cancer has been reported for many low-dose rate (LDR) studies, with an estimated loss of local control ranging from 0.3 to 1.6% per day of treatment prolongation. Since the treatment schedule for fractionated high-dose rate intracavitary brachytherapy (HDRICB) is not directly comparable with that for low-dose rate studies, this report aims to evaluate the adverse effect of treatment prolongation specifically for cervical cancer treated with HDRICB. MATERIAL AND METHODS: From September 1992 to December 1997, 257 patients diagnosed with uterine cervical cancer (35 Ib, 26 IIa, 122 IIb, 10 IIIa, 57 IIIb, 7 IVa), who underwent external radiotherapy combined with between two and four courses of HDRICB and a minimum of 3 years of follow-up (median 57 months), were analyzed. Treatment consisted of irradiation of the whole pelvis with 44-45 Gy consisting of 22-25 fractions by 5 weeks, with the dose boosted to 54-58 Gy (with central shielding) for patients diagnosed as FIGO stage IIb-IVa bilateral parametrial disease. HDRICB was performed using an Ir-192 remote afterloading technique at 1-week intervals. The standard prescribed dose for each course of HDRICB was 7.2 Gy to point A for three insertions (before July 1995), or 6.0 Gy to point A for four insertions (after July 1995). Total prescribed point A doses (external beam radiotherapy+HDRICB) ranged from 58 to 71.6 Gy (median, 65.6 Gy) for stage IB-IIA, while analogous dosage for larger lesions (stage IIb-IVa) ranged from 59 to 75.6 Gy (median, 65.6 Gy). Kaplan-Meier and multivariate analyses were used to test the effect of treatment time on pelvic control rate (PCR) and cause-specific survival (CSS) at 5 years. RESULTS: Median treatment time was 63 days. For all stages of disease, the 5-year CSS and PCR were significantly different comparing treatment times of less than and greater than or equal to 63 days [83% and 65% (P=0.004], 93% and 83% (P=0.02), respectively]. These associations were also significant for stage Ib/IIa [97% and 79% (P=0.01), and 100% and 87% (P=0.02), respectively), but not for stage IIb [75% and 72% (P=0.79), and 93% and 87% (P=0.83), respectively] or stage III [66% and 49% (P=0.2), and 83% and 72% (P=0.21), respectively]. Multivariate analysis identified three prognostic factors for CSS, stage (P<0.001), tumor response to external RT (P=0.001), and overall treatment time (OTT; P=0.006). Prognostic factors for pelvic failure were stage (P<0.001), tumor response to external RT (P=0.001), and OTT (P=0.03). Prolongation of treatment time resulted in a daily decrease in pelvic control rate of 0.67% overall, and 0.43% for stage Ib-IIa, 0.57% for stage IIb, and 0.73% for stage III patients. CONCLUSION: Analysis of the data from the current study demonstrates that the adverse effect of treatment prolongation was observed later in the treatment course for the high-dose rate (HDR) series compared to the LDR analog, however, treatment-time prolongation still negatively influenced the cause-specific survival and pelvic control rate for both dosage groups.     

我国原料药产业的发展策略

经济全球化进程的加快，中国加入世贸组织，为我国医药产业国际化发展带来了机遇。     

保罗样激酶基因沉默体外抑制胶质瘤细胞侵袭与生长

目的观察保罗样激酶1基因(plk1)沉默对胶质瘤细胞株-H4体外生长的抑制作用,探讨plk1基因作为胶质瘤治疗靶点的可行性。方法化学合成小片断干扰RNA(siRNA)抑制plk1基因的表达,Western blot检测plk1蛋白质的表达变化,流式细胞仪检测H4细胞周期分布及凋亡程度的变化,体外侵袭实验检测H4细胞侵袭能力的变化,MTT法检测H4细胞增殖速度的变化。结果经siRNA作用48h后,plk1蛋白质水平明显降低;较多的H4细胞聚集于G2/M期附近(P<0.05);细胞凋亡明显上升(P<0.05);细胞体外侵袭能力下降(P<0.05);增殖速度明显缓于对照组(P< 0.05)。结论靶向plk1的siRNA可在体外抑制胶质瘤细胞H4的侵袭与增殖,plk1有可能成为新的潜在胶质瘤治疗靶点。     

徐元庚老中医治疗肛肠疾病学术经验简介

徐元庚老中医是我院肛肠科奠基人之一,徐老年逾花甲,幼年攻读中医典籍,博采众长,徐老积40余年丰富临床经验对肛肠疾病治疗确有独到之处,发表论文40余篇,并编著《痔瘘疾病临床指南》一书。现就笔者往昔随师学习的点滴体会简述如下:1 熟读经旨,著书立说徐老出身于中医世家,幼承庭训,勤奋研读经典,深究其理,对《内经》、《伤寒》、《金匮》至今仍能背诵如流。在治学方面,主张志于医者,在熟读经典,而后逐步参悟经旨,阅读诸家医集,抱着实事求是的客观态度,掌握取长舍短,去粗存精的学习方法,以防食古不化,或断章取     

亚低温对大鼠短暂性脑缺血迟发性神经元死亡的影响

目的 观察亚低温（33℃）对大鼠短暂性脑缺血后神经元的保护作用。方法 32只DS大鼠分为假手术组、常温缺血组和即刻亚低温组，采用尼氏体亚甲蓝特殊染色观察存活神经元、原位细胞凋亡检测法（TUNEL染色）检测及电镜观察脑缺血后大鼠CA1区神经元凋亡情况。结果 与假手术组相比，常温缺血组海马CA1区存活的锥体细胞数目减少（P＜0．01）；与常温缺血组相比，亚低温缺血组海马CA1区存活的锥体细胞数目明显增多（P＜0．01）。亚低温缺血组大鼠海马CA1区TUNEL染色阳性细胞数目明显少于常温缺血组（P＜0．01）。结论 脑缺血后迟发性神经元死亡很可能通过凋亡途径，亚低温对缺血后神经元的保护作用与减少神经元凋亡有关。